Skip to main content

Kimyrsa Side Effects

Generic name: oritavancin

Medically reviewed by Last updated on Nov 8, 2023.

Note: This document contains side effect information about oritavancin. Some dosage forms listed on this page may not apply to the brand name Kimyrsa.

Applies to oritavancin: intravenous powder for solution.

Serious side effects of Kimyrsa

Along with its needed effects, oritavancin (the active ingredient contained in Kimyrsa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking oritavancin:

Less common

Less common

Incidence not known

Other side effects of Kimyrsa

Some side effects of oritavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to oritavancin: intravenous powder for injection.


In pooled clinical trials, serious side effects were reported in 5.8% of patients treated with this drug (compared to 5.9% treated with vancomycin). Cellulitis was the serious side effect reported most often with both drugs.

This drug was discontinued due to side effects in 3.7% of patients, most often due to cellulitis and osteomyelitis.

The most commonly reported side effects included nausea, headache, vomiting, limb and subcutaneous abscesses, and diarrhea.[Ref]


Common (1% to 10%): Cellulitis, limb abscess, pruritus, rash, subcutaneous abscess, urticaria

Uncommon (0.1% to 1%): Erythema multiforme, leukocytoclastic vasculitis[Ref]


Common (1% to 10%): Constipation, diarrhea, nausea, vomiting

Frequency not reported: Clostridium difficile associated diarrhea[Ref]


Common (1% to 10%): Abnormal liver function tests, increased ALT, increased AST

Uncommon (0.1% to 1%): Blood bilirubin increased

Frequency not reported: Increased total bilirubin[Ref]


Common (1% to 10%): Infusion site erythema, infusion site phlebitis, infusion site reactions[Ref]

Infusion site reactions included extravasation, induration, infusion site erythema, infusion site phlebitis, peripheral edema, pruritus, and rash.[Ref]


Common (1% to 10%): Extravasation, induration

Frequency not reported: Infusion related reactions[Ref]


Common (1% to 10%): Peripheral edema, tachycardia

Uncommon (0.1% to 1%): Flushing[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache[Ref]


Common (1% to 10%): Anemia

Uncommon (0.1% to 1%): Eosinophilia, thrombocytopenia[Ref]


Common (1% to 10%): Myalgia

Uncommon (0.1% to 1%): Osteomyelitis, tenosynovitis[Ref]


Uncommon (0.1% to 1%): Angioedema, hypersensitivity/hypersensitivity reactions[Ref]


Uncommon (0.1% to 1%): Bronchospasm, wheezing[Ref]


Uncommon (0.1% to 1%): Hyperuricemia, hypoglycemia[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. (2014) "Product Information. Orbactiv (oritavancin)." The Medicines Company

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.